Remission as defined by the SIGH-SAD [ Time Frame: 28 (visit window from 26 to 30 days) days after the inclusion day ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Decrease of the severity of symptoms as assessed by SIGH-SAD, Hamilton anxiety scale, and Beck depression inventory-21 [ Time Frame: 28 (visit window from 26 to 30 days) days ] [ Designated as safety issue: No ]

In this arm, patients will not get any bright-light therapy in a double-blind setting

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

a patient has, according to the DSM-IV-TR, a Major depression, recurrent episode, seasonal pattern, "moderate" or "severe" (classification code 296.32 and 296.33)

HAMD-21 (included in the SIGH-SAD) sum score is ≥ 22

patient is over 18 years

patient can read and understand the subject information sheet

patient has signed the informed consent form

patient is not pregnant

Exclusion Criteria:

patient has a lifetime psychotic disorder

patient has a DSM-IV Axis I disorder other than some anxiety disorder evaluated by MINI

patient has some DSM-IV-TR Axis II disorder, which is likely to interfere with the study treatment according to the investigator

patient has alcohol or some other substance use dependence or misuse

life-time suicide attempt, or any thought of suicide during the last month

patients has some unstable somatic disorder

patient uses some medication on regular basis

patient uses some herbal psychotropic agencies

patient is, in the opinion of the investigator, unsuitable for any reason

patient is a member of the site personnel or their immediate families

patient has had bright light therapy during the current episode

patient has some eye disease (patient can, however, be myopic or hyperopic)

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01030276